Corcept Therapeutics | CORT - Cash And Equivalent


Corcept Therapeutics reported $111.04M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
ANI Pharmaceuticals USD 360.21M 49.04M Jun/2026
Ardelyx USD 31.21M 36.79M Mar/2026
Aurora Cannabis CAD 64.69M 8.33M Mar/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Canopy Growth CAD 364.68M 6.64M Mar/2026
Corcept Therapeutics USD 111.04M 2.3M Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
Merck USD 6.85B 1.52B Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Novartis USD 7.62B 739M Jun/2026
Novartis USD 6.88B 2.68B Mar/2026
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 205.88M 61.57M Jun/2026
Pfizer USD 976M 727M Jun/2026
Supernus Pharmaceuticals USD 179.95M 4.92M Jun/2026
TG Therapeutics USD 612.25M 170.04M Jun/2026